Persistent sexual side effects after SSRI discontinuation.
Csoka
Antonei B
AB
Shipko
Stuart
S
D000328:Adult; D000728:Androgens / Q000008:administration & dosage; D001007:Anxiety / Q000188:drug therapy; D016642:Bupropion / Q000008:administration & dosage; D000077465:Cabergoline; D015283:Citalopram / Q000009:adverse effects; D003866:Depressive Disorder / Q000188:drug therapy; D018491:Dopamine Agonists / Q000008:administration & dosage; D018765:Dopamine Uptake Inhibitors / Q000008:administration & dosage; D004873:Ergolines / Q000008:administration & dosage; D005260:Female; D005473:Fluoxetine / Q000009:adverse effects; D006801:Humans; D008297:Male; D008996:Monoamine Oxidase Inhibitors / Q000008:administration & dosage; D010879:Piperazines / Q000008:administration & dosage; D010946:Plants, Medicinal; D011687:Purines; D012642:Selegiline / Q000008:administration & dosage; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*; D020280:Sertraline / Q000009:adverse effects; D020018:Sexual Dysfunctions, Psychological / Q000139:chemically induced* / Q000188:drug therapy; D000068677:Sildenafil Citrate; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy; D013450:Sulfones; D013739:Testosterone / Q000008:administration & dosage; D013997:Time Factors; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000008:administration & dosage
D000728:Androgens; D016642:Bupropion; D000077465:Cabergoline; D015283:Citalopram; D018491:Dopamine Agonists; D018765:Dopamine Uptake Inhibitors; D004873:Ergolines; D005473:Fluoxetine; D008996:Monoamine Oxidase Inhibitors; D010879:Piperazines; D011687:Purines; D012642:Selegiline; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline; D000068677:Sildenafil Citrate; D013450:Sulfones; D013739:Testosterone; D014665:Vasodilator Agents